In Vivo is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183
Printed By
Blockbuster status has long been the ultimate goal of drug development, defined as a sales potential of more than $1bn. The economics of drug development, and in fact of the entire biopharma industry, very much rely on these few gems that provide the returns to compensate for the long development pathway and often several billion dollars of investment per new molecular entity.
